Carcinoma de mama masculino: um relato de caso / Male breast carcinoma: a case report

Rodrigo Alves Faria, Sônia Alves Gouvêa, Cleide dos Santos Coelho, Wilson Denadai, Sergio Wilson Alves Pereira, Neuzimar Rodolfo Serafim

Abstract


O câncer de mama masculino é uma doença raramente diagnosticada em homens, correspondendo em apenas 1% dentre todos os casos de câncer de mama. Os principais fatores de risco relacionados incluem histórico familiar, doenças crônicas, terapia hormonal, obesidade e alterações genéticas. A forma diagnóstica mais frequentemente encontrada é o carcinoma ductal invasivo, que se apresenta de forma indolor como uma massa subareolar sendo diagnosticada por métodos de imagens seguido por biópsia. O tratamento preconizado é cirúrgico, seguido ou não de quimioterapia, radiologia e hormonioterapia. O câncer de mama masculino apresenta pior prognóstico em relação ao câncer feminino, devido a fatores como menor tecido mamário, localização e disseminação precoce. O presente trabalho propõe a apresentação de um relato de caso de câncer de mama masculino, objetivando a elucidação da incidência e comorbidades associadas.


Keywords


Câncer Masculino, Mama, Carcinoma Ductal Invasivo.

References


C O'MALLEY, S SHEMA, E WHITE et al: Incidência do câncer de mama masculino na Califórnia, 1988-2000: Variação racial / étnica em 1759 homens Breast Cancer Res Treat 93:145 - 150, 2005.

BA BALASUBRAMANIAN, K DEMISSIE, BF CRABTREE et al: diferenças raciais na terapia sistêmica adjuvante para o câncer de mama precoce entre os beneficiários MedicaidBreast J 16: 162 - 168, 2010.

NH GORDON, JP CROWE, J BRUMBERG et al: Fatores socioeconômicos e raça na recorrência e na sobrevida do câncer de mama Am J Epidemiol 135: 609 - 618, 1992.

HELMNEH M. SINESHAW, RACHEL A. FREEDMAN, ELIZABETH M. WARD, W. DANA FLANDERS, and AHMEDIN JEMAL. Black/White Disparities in Receipt of Treatment and Survival Among Men With Early-Stage Breast Cancer. J Clin Oncol 33:2337-2344, 2015;.

NG, M et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, London, v.384, n.9945, p. 766-781, 2014. Disponível em: . Acesso em: 07 fev.2018.

KAIDAR-PERSON O, BAR-SELA G, PERSON B. The two major epidemics of the twenty-first century: obesity and cancer. Obes Surg. 2011 Nov;21(11):1792-7.

WOLIN KY, CARSON K, COLDITZ GA. Obesity and cancer. Oncologist. 2010;15(6):556-65.

ROBERTS DL, DIVE C, RENEHAN AG. Biological mechanisms linking obesity and cancer risk: new perspectives. Annu Rev Med. 2010; 61:301-16.

COTTAM D, FISHER B, ZIEMBA A, ATKINSON J, GRACE B, WARD DC, et al. Tumor growth factor expression in obesity and changes in expression with weight loss: another cause of increased virulence and incidence of cancer in obesity. Surg Obes Relat Dis. 2010 Sep-Oct;6(5):538-41.

PRIETO-HONTORIA PL, PÉREZ-MATUTE P, FERNÁNDEZ-GALILEA M, BUSTOS M, MARTÍNEZ JA, MORENO-ALIAGA MJ. Role of obesity-associated dysfunctional adipose tissue in cancer: a molecular nutrition approach. Biochim Biophys Acta. 2011 Jun;1807(6):664-78.

BONFIM, RJA et al. Câncer de mama no homem: análise dos aspectos epidemiológicos, clínicos e terapêuticos em serviço formal brasileiro. Revista Brasileira de Oncologia Clínica, São Luis, v. 10, n. 37, p.90-96, 28 nov. 2013. Disponível em: . Acesso em: 28 jun. 2019.

HSING, AW, JOSEPH KM, PIERLUIGI C, HARVEY T. CO CHIEN, and JOSEPH FF. "Risk Factors for Male Breast Cancer (United States)." Cancer Causes & Control 9, no. 3 (1998): 269-75. http://www.jstor.org/stable/3552830. Acesso em: 28 jun. 2019.

KORNEGOOR R, VERSCHUUR-MAES AH, BUERGER H, HOGENES MC, DE BRUIN PC, OUDEJANS JJ, et al. Molecular subtyping of male breast cancer by immunohistochemistry. Mod Pathol 2012;25(3): 398 e 404.

JOHANSSON I, KILLANDER F, LINDERHOLM B, HEDENFALK I. Molecular profiling of male breast cancer e lost in translation? Int J Biochem Cell Biol 2014; 53: 526 e 35.

SHAABAN AM, BALL GR, BRANNAN RA, CSERNI G, DI BENEDETTO A, DENT J, et al. A comparative biomarker study of 514 matched cases of male and female breast cancer reveals gender-specific biological differences. Breast Cancer Res Treat 2012;133(3): 949 e 58.

HILL TD, KHAMIS HJ, TYCZYNSKI JE, BERKEL HJ. Comparison of male and female breast cancer incidence trends, tumor characteristics, and survival. Ann Epidemiol 2005;15(10):773 e 80.

HASEBE T, TSUDA H, HIROHASHI S, SHIMOSATO Y, IWAI M, IMOTO S, et al. Fibrotic focus in invasive ductal carcinoma: an indicator of high tumor aggressiveness. Jpn J Cancer Res 1996;87(4): 385 e 94.

LEE AH, PINDER SE, MACMILLAN RD, MITCHELL M, ELLIS IO, ELSTON CW, et al. Prognostic value of lymphovascular invasion in women with lymph node negative invasive breast carcinoma. Eur J Cancer 2006;42(3):357 e 62.

ANDERSON WF, JATOI I, TSE J et al. Câncer de mama masculino: comparação populacional com o câncer de mama feminino. J Clin Oncol 2010; 28: 232-239.

ANDERSON WF, ALTHUIS D. O câncer de mama masculino é semelhante ou diferente do câncer de mama feminino? Breast Cancer Res Treat 2004; 83: 77-86.

KORDE AL, ZUJEWSKI JA. Encontro multidisciplinar sobre câncer de mama masculino: resumo e recomendações de pesquisa. J Clin Oncol 2010; 28: 2114-2122.

OTTINI G, PALLI D. Câncer de mama masculino. Crit Rev Oncol Hematol 2010; 73: 141–155.

DEB S, JENE N, KCONFAB I et al. A análise genotípica e fenotípica do câncer de mama masculino mostra a sub-representação dos subtipos basais e HER2 em carcinomas associados a BRCA. Câncer de BMC 2012; 12: 510.

JOHANSSON I, NILSSON C, BERGLUND P et al. O perfil de expressão gênica de câncer de mama masculino primário revela dois subgrupos únicos e identifica a N-acetiltransferase-1 (NAT1) como um novo biomarcador prognóstico. Res câncer de mama: BCR2012; 14: R31.

OTTINI L, SILVESTRI V, RIZZOLO P et al. Características clínicas e patológicas de pacientes masculinos com câncer de mama positivos para BRCA e negativos para BRCA: resultados de um estudo colaborativo multicêntrico na Itália. Câncer de Mama Res Treat 2012; 134: 411-418.

DEB S, DO H, BYRNE D et al. Mutações no gene PIK3CA são freqüentemente observadas no BRCAX, mas não no câncer de mama masculino associado ao BRCA2. Res câncer de mama 2013; 15: R69

KORDE LA, ZUREWSKI JA, KAMIN L et al, reunião multidisciplinar sobre câncer de mama masculino: resumo e recomendações de pesquisa. J Clin Oncol 2010; 28: 2114-2122

GIORDANO SH. Uma revisão do diagnóstico e manejo do câncer de mama masculino. Oncologista 2005; 10: 471-479.

Instituto Nacional de Câncer José Alencar Gomes da Silva: A situação do câncer de mama no Brasil: síntese de dados dos sistemas de informação. / Instituto Nacional de Câncer José Alencar Gomes da Silva. – Rio de Janeiro: INCA, 2019. 85 p. ISBN 978-85-7318-377-1 (versão eletrônica)

KR BAUER, M. BROWN, RD CRESS, et al: Análise descritiva do receptor de estrogênio (ER) -negativo, receptor de progesterona (PR) -negativo, e câncer de mama HER2-negativo invasivo, o chamado fenótipo triplo-negativo: A população- estudo baseado do Registro de Câncer da Califórnia Cancer 109: 1721 - 1728, 2007

BRAY, F. et al. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for Cancers in 185 Countries. CA: a Cancer Journal for Clinicians, v. 68, n. 6, p. 394-424, 2018.

DG EVANS, I SUSNERWALA, J DAWSON, et al: Risco de câncer de mama em portadores de BRCA2 masculino J Med Genet 47: 710 - 711, 2010.

LA BRINTON, MB COOK, V MCCORMACK, et al: Fatores de risco antropométricos e hormonais para o câncer de mama masculino: Resultados do projeto de câncer de mama masculino J Nat Cancer Inst 106: djt465 , 2014

OTTINI L. Male breast cancer: a rare disease that might uncover underlying pathways of breast cancer. Nat Rev Cancer 14(10): 643, 2014.

BRANT JM, KELLER L, MCLEOD K, et al: Chronic and refractory pain: A systematic review of pharmacologic management in oncology. Clin J Oncol Nurs 21:31-53, 2017 (suppl 3) check page numer

PEIXOTO RD, HAWLEY P: Intravenous lidocaine for cancer pain without electrocardiographic monitoring: A retrospective review. J Palliat Med 18:373-377, 2015

SALADORES P, MU¨ RDTER T, ECCLES D, et al: Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer. Pharmacogenomics J 15:84-94, 2015

SANCHEZ-SPITMAN A, DEZENTJE´ V, SWEN J, et al: Tamoxifen pharmacogenetics and metabolism: Results from the prospective CYPTAM study. J Clin Oncol 37:636-646, 2019

RIVENBARK AG, O'CONNOR SM, COLEMAN WB. Heterogeneidade celular e molecular no câncer de mama: desafios para a medicina personalizada. Am J Pathol 2013; 183: 1113–1124.

CALLE EE, RODRIGUEZ C, WALKER-THURMOND K, THUN MJ. Overweight, obesity and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003 Apr 24;348(17):1625-38.

CALLE EE, KAAKS R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer. 2004 Aug;4(8):579-91.

INTERNATIONAL AGENCY FOR RESEARCH ON CANCER. Weight Control and Physical Activity, Volume 6 Lyon: International Agency for Research Cancer 2002:1-315, 30-4.

VERMEULEN MA, SLAETS L, CARDOSO F et al, Caracterização patológica do câncer de mama masculino: resultados do Programa Internacional de Câncer de Mama do EORTC 10085 / TBCRC / BIG / NABCG. Eur J Cancer 2017; 82: 219-227.

SHAABAN AM, BOLA GR, BRANNAN RA et al, Um estudo comparativo de biomarcadores de 514 casos combinados de câncer de mama masculino e feminino revela diferenças biológicas específicas de gênero. Câncer de Mama Res Treat 2012; 133: 949-958.

LEONE JP, LEONE J, ZWENGER AO. Et al. Significado prognóstico dos subtipos tumorais no câncer de mama masculino: um estudo de base populacional. Câncer de Mama Res Treat 2015; 152: 601–609

SIEGEL RL, MILLER KD, JEMAL A. Cancer statistics, 2015. CA Cancer J Clin 2015;65(1):5e29.

GIORDANO SH, COHEN DS, BUZDAR AU, PERKINS G, HORTOBAGYI GN. Breast carcinoma in men: a population-based study. Cancer 2004;101(1):51e7

CARDOSO, C. F. et al. Characterization of male breast cancer: results of the EORT C 10085/TBCRC/BIG/NABCG

International Male Breast Cancer Program. Annals of Oncology, v. 29, n. 2, p. 405–417, 2018.

KREITER E, RICHARDSON A, POTTER J, e outros: Cancro da mama: Tendências na incidência internacional em homens e mulheres. Br J Cancer 110: 1891 - 1897, 2014.

HODGSON NC, BUTTON JH, FRANCESCHI D et al. Male breast cancer: is the incidence increasing? Ann Surg Oncol 2004; 11(8): 751–755.

SPEIRS V, SHAABAN AM. The rising incidence of male breast cancer. Breast Cancer Res Treat 2009; 115(2): 429–430.

BRINTON LA, RICHESSON DA, GIERACH GL et al. Prospective evaluation of risk factors for male breast cancer. J Natl Cancer Inst 2008; 100(20): 1477– 1481.

ATRAM-HOANG S, MORAN EM, ANTON-CULVER H et al. A pilot study of male breast cancer in the Veterans Affairs healthcare system. J Environ Pathol Toxicol Oncol 2010; 29(3): 235–244.

OTTINI L, MASALA G, D’AMICO C et al. BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer: a population-based study in Italy. Cancer Res 2003; 63(2): 342–347.

FRIEDMAN LS, GAYTHER SA, KUROSAKI T et al. Mutation analysis of BRCA1 and BRCA2 in a male breast cancer population. Am J Hum Genet 1997; 60(2): 313–319.

DING YC, STEELE L, KUAN CJ et al. Mutations in BRCA2 and PALB2 in male breast cancer cases from the United States. Breast Cancer Res Treat 2011; 126(3): 771–778.

BLANCO A, DE LA HOYA M, BALMANA J et al. Detection of a large rearrangement in PALB2 in Spanish breast cancer families with male breast cancer. Breast Cancer Res Treat 2012; 132(1): 307–315.

SILVESTRI V, RIZZOLO P, ZANNA I et al. PALB2 mutations in male breast cancer: a population-based study in Central Italy. Breast Cancer Res Treat 2010; 122(1): 299–301.

SAUTY DE CHALON A, TEO Z, PARK DJ et al. Are PALB2 mutations associated with increased risk of male breast cancer? Breast Cancer Res Treat 2010; 121(1): 253–255.

GILBERT SF, SOLIMAN AS, INIESTA M et al. Androgen receptor polyglutamine tract length in Egyptian male breast cancer patients. Breast Cancer Res Treat 2011; 129(2): 575–581.

YOUNG IE, KURIAN KM, MACKENZIE MA et al. The CAG repeat within the androgen receptor gene in male breast cancer patients. J Med Genet 2000; 37(2): 139–140.

YOUNG IE, KURIAN KM, ANNINK C et al. A polymorphism in the CYP17 gene is associated with male breast cancer. Br J Cancer 1999; 81(1): 141–143

WASIELEWSKI M, DEN BAKKER MA, VAN DEN OUWELAND A et al. CHEK2 1100delC and male breast cancer in the Netherlands. Breast Cancer Res Treat 2009; 116(2): 397–400.

OHAYON T, GAL I, BARUCH RG et al. CHEK2*1100delC and male breast cancer risk in Israel. Int J Cancer 2004; 108(3): 479–480.

SYRJAKOSKI K, KUUKASJARVI T, AUVINEN A et al. CHEK2 1100delC is not a risk factor for male breast cancer population. Int J Cancer 2004; 108(3): 475–476.

JOHNSON KC, PAN S, MAO Y. Risk factors for male breast cancer in Canada, 1994–1998. Eur J Cancer Prev 2002; 11(3): 253–263.

EWERTZ M, HOLMBERG L, TRETLI S et al. Risk factors for male breast cancer—a case-control study from Scandinavia. Acta Oncol 2001; 40(4): 467–471.

HULTBORN R, HANSON C, KOPF I et al. Prevalence of Klinefelter’s syndrome in male breast cancer patients. Anticancer Res 1997; 17(6D): 4293–4297.

BRINTON LA, CARREON JD, GIERACH GL et al. Etiologic factors for male breast cancer in the U.S. Veterans Affairs medical care system database. Breast Cancer Res Treat 2010; 119(1): 185–192.

MEDRAS M, FILUS A, JOZKOW P et al. Breast cancer and long-term hormonal treatment of male hypogonadism. Breast Cancer Res Treat 2006; 96(3): 263–265.

NG, M. et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, London, v.384, n.9945, p. 766-781, 2014. Disponível em: . Acesso em: 07 fev.2018.

SOLANGE S. PEREIRA, JACQUELINE I. ALVAREZ-LEITE. Low-Grade Inflammation, Obesity, and Diabetes. Metabolism (R Pasquali, Section Editor) Current Obesity Reports. 2014; 3(4):422-431.

OBESITY AND OVERWEIGHT. Geneva: World Health Organization, 2017b. Disponível em: . Acesso em: 14 jan.2018. January 2018).

LEE SC, ELLIS RJ. Male breast cancer during finasteride therapy. J Natl Cancer Inst 2004; 96(4): 338–339.

YONEDA S, YOSHIKAWA M, YAMANE Y et al. Breast cancer developed in a male patient with liver cirrhosis bearing hepatocellular carcinoma. Am J Gastroenterol 2000; 95(2): 556–557.

THELLENBERG C, MALMER B, TAVELIN B et al. Second primary cancers in men with prostate cancer: an increased risk of male breast cancer. J Urol 2003; 169(4): 1345–1348.

RON E, IKEDA T, PRESTON DL et al. Male breast cancer incidence among atomic bomb survivors. J Natl Cancer Inst 2005; 97(8): 603–605.

FENTIMAN IS, FOURQUET A, HORTOBAGYI GN. Male breast cancer. Lancet 2006; 367(9510): 595–604.

MATANOSKI GM, BREYSSE PN, ELLIOTT EA. Electromagnetic field exposure and male breast cancer. Lancet 1991; 337(8743): 737.

TYNES T, ANDERSEN A. Electromagnetic fields and male breast cancer. Lancet 1990; 336(8730): 1596.

ROSENBAUM PF, VENA JE, ZIELEZNY MA et al. Occupational exposures associated with male breast cancer. Am J Epidemiol 1994; 139(1): 30–36.

HANSEN J. Elevated risk for male breast cancer after occupational exposure to gasoline and vehicular combustion products. Am J Ind Med 2000; 37(4): 349–352.

PALLI D, MASALA G, MARIANI-COSTANTINI R et al. A gene-environment interaction between occupation and BRCA1/BRCA2 mutations in male breast cancer? Eur J Cancer 2004; 40(16): 2474–2479.

VILLENEUVE S, CYR D, LYNGE E et al. Occupation and occupational exposure to endocrine disrupting chemicals in male breast cancer: a case-control study in Europe. Occup Environ Med 2010; 67(12): 837–844.

SORENSEN HT, OLSEN ML, MELLEMKJAER L et al. The intrauterine origin of male breast cancer: a birth order study in Denmark. Eur J Cancer Prev 2005; 14(2): 185–186.

DB EVANS, RW CRICHLOW: Carcinoma da mama masculina e síndrome de Klinefelter: Existe uma associação? CA Câncer J Clin 37: 246 - 251, 1987.

AJ SASCO, AB LOWENFELS, P PASKER-DE JONG: Artigo de revisão: Epidemiologia do câncer de mama masculino - Uma meta-análise de estudos caso-controle publicados e discussão de fatores etiológicos selecionados Int J Cancer 53: 538 - 549, 1993.

VM BASHAM, JM LIPSCOMBE, JM WARD, et al: BRCA1 e BRCA2 mutações em um estudo de base populacional de câncer de mama masculino Breast Cancer Res 4: R2, 2002.

NASCIMENTO, FB; PITTA, MGR; REGO, MJBM. Análise dos principais métodos de diagnóstico de câncer de mama como propulsores no processo inovativo. Arq Med, Porto, v. 29, n. 6, p. 153-159, dez. 2015 . Disponível em . Acesso em 12 ago. 2019.




DOI: https://doi.org/10.34119/bjhrv3n1-005

Refbacks

  • There are currently no refbacks.